Progress and strategies for patients with relapsed and refractory acute myeloid leukemia

Current Opinion in Hematology

Volumn 14, Issue 2, 2007, Pages 130-137

  Litzow, Mark R ^a  

^a Mayo Clinic   (United States)

Author keywords

Blood or marrow transplantation; Gene expression profiles; Immunotherapy; Molecular targets; Reduced intensity conditioning

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; ANTILEUKEMIC AGENT; BEVACIZUMAB; CARBOPLATIN; CEP 701; CLOFARABINE; CLORETAZINE; CYTARABINE; FLAVOPIRIDOL; FREUND ADJUVANT; GEMTUZUMAB OZOGAMICIN; LESTAURTINIB; LEUKEMIA ANTIGEN; MIDOSTAURIN; MITOXANTRONE; MONOCLONAL ANTIBODY; MYELOBLASTIN; OBLIMERSEN; RAPAMYCIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; TANDUTINIB; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; VALPROIC ACID; WILM TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; GENE MUTATION; GENE OVEREXPRESSION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNIZATION; MONOTHERAPY; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; REMISSION; REVIEW; TYPHLITIS; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ALGORITHMS; HUMANS; LEUKEMIA, MYELOID; PROGNOSIS; SALVAGE THERAPY;

EID: 33846594363     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32801684ef     Document Type: Review

References (47)

1. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukaemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331:896-903.
2. Estey EH. General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. Semin Hematol 2006; 43:89-95.
3. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730-737.
4. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92:2322-2333.
5. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96:4075-4083.
6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100:2292-2302.
7. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100:1532-1542.
8. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100:59-66.
9. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352:254-266. This seminal study assessed the prognostic significance of the presence of cytoplasmic NPM in blast cells of patients with AML and showed that specimens with cytoplasmic NPM carried mutations of the NPM gene but conferred a favorable prognosis for patients with AML.
10. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106:3733-3739.
11. Marcucci G, Baldus CD, Ruppert AS, et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 2005; 23:9234-9242.
12. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24:3904-3911.
13. Baldus CD, Thiede C, Soucek S, et al. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J Clin Oncol 2006; 24:790-797.
14. Bullinger L, Dohner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350:1605-1616.
15. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350:1617-1628.
16. Mrozek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2006; Sep 7 [Epub ahead of print].
17. Kern W, Schoch C, Haferlach T, et al. Monitoring of minimal residual disease in acute myeloid leukemia. Crit Rev Oncol Hematol 2005; 56:283-309. This excellent review summarizes the status of monitoring MRD in AML.
18. Rowe JM, Xiaochun L, Cassileth PA, et al. Very poor survival of patients wtih AML who relapse after achieving a first complete remission: The Eastern Cooperative Oncology Group Experience (Abstract 546). Blood 2005; 106:162a.
19. Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma 2002; 43:1715-1727.
20. Estey E, Thall P, David C. Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 1997; 40 (Suppl):S9-S12.
21. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23:1969-1978. This paper describes an easily applied prognostic index using clinical features for adult patients with AML in first relapse.
22. Tang JM, Meng FY, Chen AW. Gene expression profile of refractory acute myeloid leukemia (M2a). Ai Zheng 2005; 24:676-679.
23. Kaufmann SH, Karp JE, Letendre L, et al. Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res 2005; 11:6641-6649.
24. Karp JE, Smith BD, Greer J, et al. Phase II clinical trial of flavopiridol (FL) followed by ARA-C and mitoxantrone (AM) for adults with relapsed and refractory acute leukemias (Abstract 2784). Blood 2005; 106:781a.
25. Giles F, Verstovsek S, Faderl S, et al. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leuk Res 2006; 30:1591-1595.
26. Giles F, O'Brien S, Rizzieri D, et al. Cloretazine (VNP40101M) is active in elderly untreated poor risk patients with acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS) (Abstract 2786). Blood 2006; 106:781a.
27. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005; 105:940-947. The authors have conducted an excellent phase I-II study looking at the use of clofarabine with Ara-C in patients with relapsed AML and show a relatively high response rate without excessive toxicity.
28. Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105:2527-2534. This trial described the use of a novel agent for the treatment of AML where the molecular mechanism is well identified.
29. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2006; Aug 1 [Epub ahead of print].
30. Lubbert M, Ruter B, Schmid M, et al. Continued low-dose decitabine (DAC) is an active first-line treatment of older AML patients: first results of a multicenter phase II study (Abstract 1852). Blood 2006; 106:527a.
31. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase I/II study of the combination of 5-aza-2′ -deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108:3271-3279.
32. Moore J, Seiter K, Kolitz J, et al. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res 2006; 30: 777-783.
33. Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizu-mab. Clin Cancer Res 2004; 10:3577-3585.
34. Levis MJ, Smith BD, Beran M, et al. A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition (Abstract 403). Blood 2006; 106:121a.
35. Stone RM, Fischer T, Paquette R, et al. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML (Abstract 404). Blood 2006; 106:121a.
36. De Angelo DJ, Stone RM, Heaney ML, et al. Phase I clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics and pharmacodynamics. Blood 2006; 15 Aug [Epub ahead of print].
37. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005; 104:1442-1452.
38. Qazilbash MH, Weider E, Rios R, et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission inpatients with myeloid leukemia (Abstract 259). Blood 2004; 104:77a.
39. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101:13885-13890.
40. Rusakiewicz S, Molldrem JJ. Immunotherapeutic peptide vaccination with leukemia-associated antigens. Curr Opin Immunol 2006; 18:599-604.
41. Appelbaum FR, Pearce SF. Hematopoietic cell transplantation in first complete remission versus early relapse. Best Pract Res Clin Haematol 2006; 19:333-339.
42. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108:1092-1099. The authors describe a novel approach to combining reinduction chemotherapy with a transplant in short sequence to bring about a durable clinical response in a significant minority of patients.
43. Lazarus HM, Perez WS, Klein JP, et al. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol 2006; 132:755-769.
44. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey fromthe Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19:2304-2312. This study retrospectively compared a large number of patients who received a RIC-BMT to those with a myeloablative BMT and showed that although the RIC-BMT patients were older and transplanted more recently, their outcomes were equivalent to those with myeloablative transplant.
45. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24:444-453.
46. Lazarus HM, Rowe JM. Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct. Leukemia 2006; 20:1673-1682.
47. O'Donnell MR, Appelbaum FR, Baer MR, et al. Acute myeloid leukemia clinical practice guidelines in oncology. JNCCN 2003; 1:520-539.